Glenmark USA launches Adapalene Gel 0.1% OTC in new pump packs

Compliance View source PDF Explain this filing

GLENMARK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.7%Reaction day

₹2295.00

prior close

₹2312.20

announcement price

After-mkt

timing

Nifty Midcap 150market+1.0%-0.3% vs market

Pharmaceuticals peers, median of 170sector+0.9%-0.2% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Midcap 150 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-1.1

15m

-1.4

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.7+1.0-0.3+0.9-0.2

Next day

-0.1+0.4-0.5+0.9-1.0

-4.5-2.0-2.4-1.4-3.1

-0.1-0.7+0.6-1.4+1.3

-0.5-0.6+0.1-1.8+1.3

-0.8+0.3-1.1-2.0+1.2

-1.9+0.0-1.9-2.5+0.6

15d

+0.2pendingpending-2.7+2.9

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Glenmark Therapeutics Inc., USA launched Adapalene Gel USP, 0.1% (OTC), an acne treatment comparable to Differin Gel, in new 15g and 45g pump packs. The product is available on Amazon and Walmart. Per Nielsen data, the addressable US OTC market for Differin Gel is about $45.8 million annually. The launch adds a new format to Glenmark's existing US dermatology portfolio.

Likely market impact

New pump format may help Glenmark win more of the $45.8 million Differin-equivalent US OTC market, modest positive for US dermatology revenue.